Coppell Advisory Solutions’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.68M Buy
+436
New +$193K 0.14% 131
2025
Q3
Sell
-6,686
Closed -$2.95M 417
2025
Q2
$2.95M Buy
6,686
+2,846
+74% +$1.31M 0.35% 54
2025
Q1
$1.93M Buy
3,840
+3,356
+693% +$1.56M 0.27% 85
2024
Q4
$193K Buy
484
+280
+137% +$130K 0.03% 281
2024
Q3
$94.4K Buy
204
+112
+122% +$53.8K 0.01% 407
2024
Q2
$43.1K Buy
+92
New +$39.9K 0.01% 537
2023
Q4
$52.9K Sell
130
-31
-19% -$11.5K 0.01% 484
2023
Q3
$46.5K Buy
161
+114
+243% +$39.9K 0.02% 326
2023
Q2
$16.4K Buy
+47
New +$15.8K ﹤0.01% 601
2023
Q1
Sell
-161
Closed -$46.5K 1067
2022
Q4
$46.5K Buy
+161
New +$49.1K 0.02% 329

Other funds holding VRTX

Coppell Advisory Solutions's VRTX Position: Q2 2026 in Review

Coppell Advisory Solutions opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 436 shares worth $1.68M. The stake represents 0.14% of the portfolio and ranks #131 among its holdings. This is a return to the name: Coppell Advisory Solutions previously reported a position in VRTX as recently as Q2 2025.

Coppell Advisory Solutions first reported a position in VRTX in Q4 2022 and has held it in 10 quarters since. The position peaked at $2.95M in Q2 2025. 1,758 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Coppell Advisory Solutions held 436 shares of Vertex Pharmaceuticals worth $1.68M as of Q2 2026.
  • Vertex Pharmaceuticals was a new Coppell Advisory Solutions position in Q2 2026.
  • Vertex Pharmaceuticals made up 0.14% of Coppell Advisory Solutions's portfolio in Q2 2026, its #131 holding.
  • Coppell Advisory Solutions first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • Coppell Advisory Solutions's Vertex Pharmaceuticals position peaked at $2.95M in Q2 2025.
  • 1,758 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Coppell Advisory Solutions's 13F filing for Q2 2026, filed 14 Aug 2026.